Research Grade Relatlimab (HB613036)

Name: Research Grade Relatlimab
Brand: abinScience
SKU: HB613036
Price: 326 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD): $

Spec:

100ug
1mg

Number:

Overview
Images
References
Datasheet

Overview

Catalog No.	HB613036
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Isotype	IgG4-kappa
Expression system	Mammalian Cells
Clonality	Monoclonal
Target	FDC, LAG3, Lymphocyte activation gene 3 protein, CD223, sLAG-3, LAG-3
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P18627
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names	BMS-986016, ONO-4482, 1673516-98-7
Background	Lymphocyte activation gene 3 protein (CD223/LAG3) is a ~57 kDa protein. Inhibitory receptor on antigen activated T-cells (1,2,3,4). Delivers inhibitory signals upon binding to ligands, such as MHC class II, its main ligand present at the surface of antigen-presenting cells (APCs), and FGL1, which is secreted by hepatocytes and certain types of tumor cells (5,6,2,7,8,4,9). Ligand-binding initiates a signaling that inhibits the T-cell receptor (TCR) in the immunological synapse, preventing T-cell activation (10). Mechanistically, ligand-binding promotes (1) ubiquitination of the KIEELE motif, unleashing the RRFSALE motif from the membrane and (2) leading to the formation of condensates with the TCR component CD3E, thereby disrupting the association between CD3E and LCK and preventing TCR activation (10,11). May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1. CD223 is the therapeutic target of relatlimab (Opdualag). References: 1. Camisaschi, C. et al. (2010) Journal of immunology (Baltimore, Md. : 1950) 184, 6545-51. PMID: 20421648 2. Ming, Q. et al. (2022) Nature immunology 23, 1031-1041. PMID: 35761082 3. Huard, B. et al. (1994) European journal of immunology 24, 3216-21. PMID: 7805750 4. Huard, B. et al. (1996) European journal of immunology 26, 1180-6. PMID: 8647185 5. Wang, J. et al. (2019) Cell 176, 334-347.e12. PMID: 30580966 6. MacLachlan, BJ. et al. (2021) European journal of immunology 51, 331-341. PMID: 32920841 7. Petersen, J. et al. (2024) Science immunology 9, eads5122. PMID: 39671469 8. Huard, B. et al. (1995) European journal of immunology 25, 2718-21. PMID: 7589152 9. Jiang, Y. et al. (2025) Cell 188, 2354-2371.e18. PMID: 40101708
Note	For research use only. Not suitable for clinical or therapeutic use.